We are live on ! Find out more
ATOS icon

Atossa Therapeutics
ATOS

10 hedge funds and large institutions have $472K invested in Atossa Therapeutics in 2017 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,010% more capital inflows, than outflows

Capital inflows: $314K | Capital outflows: $14.9K

14% more ownership

Funds ownership: 10.56% → 24.57% (+14%)

17% less funds holding

Funds holding: 12 → 10 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
10
Holders Change
-2
Holders Change %
-16.67%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$166K
2
Renaissance Technologies
Renaissance Technologies
New York
+$128K
3
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$15.1K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.29K
5
Virtu KCG Holdings
Virtu KCG Holdings
New York
+$2.16K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$9K
2
UBS Group
UBS Group
Switzerland
-$3.91K
3
Barclays
Barclays
United Kingdom
-$2K

ATOS Hedge Fund Activity: Q2 2017 in Review

10 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2017, worth a combined $472K — up 55% from $305K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of ATOS and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 4 added.

The largest buyer was Sabby Management, opening a new position worth an estimated $166K. The largest seller was Citadel Advisors, exiting entirely with an estimated $9K sold.

  • 10 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2017, down from 12 in Q1 2017.
  • Funds reported $472K of Atossa Therapeutics stock for Q2 2017, up 55% quarter-over-quarter.
  • 1 fund opened new Atossa Therapeutics positions in Q2 2017 and 3 closed out, a net change of -2 holders.
  • The largest Atossa Therapeutics buyer in Q2 2017 was Sabby Management, an estimated $166K added.
  • The largest Atossa Therapeutics seller in Q2 2017 was Citadel Advisors, an estimated $9K sold.

Based on aggregated 13F filings for Q2 2017.